Ruthenium-based core-shell nanoparticles with exceptional in vitro biocompatibility
Loading...
Date
2017-12-31
ORCID
Advisor
Referee
Mark
Journal Title
Journal ISSN
Volume Title
Publisher
Mendel University in Brno
Abstract
The current study demonstrates design preparation and characterization of biocompatible
hybrid ruthenium core-shell nanoparticles (RuNPs) coated with polyvinylpyrrolidone (PVP)
and polyoxyethylene stearate (POES). The resulting RuNPs were loaded with doxorubicin,
as model anticancer drug. Resulting complex has an exceptional stability in physiological
conditions. The cytotoxic effects of the complex were tested using cell lines representing
breast and ovarian cancers and neuroblastoma. Although bare RuNPs had only negligible
cytotoxicity, RuPDox caused an enhancement of doxorubicin cytotoxicity when compared
to free doxorubicin. RuPDox promoted significantly increased stability of doxorubicin in human
plasma and pronounced hemocompatibility assayed on human red blood cells. Results demonstrate
that biocompatible RuNPs could have a great potential as versatile nanoplatform to enhance efficiency
of anticancer therapy.
Description
Citation
Document type
Peer-reviewed
Document version
Published version
Date of access to the full text
Language of document
en
Study field
Comittee
Date of acceptance
Defence
Result of defence
Document licence
(C) Mendel University in Brno